US 12318386
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
granted A61KA61K31/4166A61K31/433
Quick answer
US patent 12318386 (Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer) held by Karyopharm Therapeutics Inc. expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Karyopharm Therapeutics Inc.
- Grant date
- Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/4166, A61K31/433, A61K31/506, A61K31/573